Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results

Abstract Background The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was desi...

Full description

Bibliographic Details
Main Authors: Andreas R. Gantenbein, Reto Agosti, Christian P. Kamm, Gunther Landmann, Niklaus Meier, Gabriele Susanne Merki-Feld, Jens A. Petersen, Heiko Pohl, Philippe Ryvlin, Christoph J. Schankin, Dragana Viceic, Chiara Zecca, Elisabeth Schäfer, Ina Meyer, Michael E. Arzt
Format: Article
Language:English
Published: BMC 2022-11-01
Series:The Journal of Headache and Pain
Subjects:
Erenumab
Migraine
Real-world evidence
Quality of life
Healthcare impact
Switzerland
Online Access:https://doi.org/10.1186/s10194-022-01515-8

Internet

https://doi.org/10.1186/s10194-022-01515-8

Similar Items